

FOI 3767

28th May 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Response:

Current patient numbers as of 8/5/26

• Adalimumab – Humira	29
• Adalimumab Biosimilar	323
• Apremilast – Otezla	no records
• Apremilast generic	no records
• Bimekizumab	18
• Brodalumab	6
• Certolizumab	7
• Deucravacitinib	0
• Dimethyl fumarate	0
• Etanercept – Enbrel	0
• Etanercept Biosimilar	<5
• Guselkumab	70
• Infliximab – Remicade	0
• Infliximab Biosimilar	11
• Ixekizumab	119
• Risankizumab	141
• Secukinumab	53
• Tildrakizumab	5
• Ustekinumab – Stelara	<5
• Ustekinumab Biosimilar	25
• Omalizumab	37
• Spesolimab	0

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition, the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the exact figures from disclosure. The Trust does not consider the disclosure of the information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

Response:

Current patient numbers as of 8/5/26

• Adalimumab – Humira	20
• Adalimumab Biosimilar	62
• Bimekizumab	0
• Certolizumab	0
• Infliximab – Remicade	0
• Infliximab Biosimilar	8
• Secukinumab	24
• Ustekinumab – Stelara	0
• Ustekinumab Biosimilar	0

Email: foi.team@southerntrust.hscni.net